Solid Biosciences Aktie
WKN DE: A2JCWM / ISIN: US83422E1055
|
23.07.2025 14:36:26
|
Solid Biosciences Gets Fast Track Designation For Gene Therapy Candidate SGT-501
(RTTNews) - Solid Biosciences Inc. (SLDB) Wednesday said it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SGT-501, the company's gene therapy candidate for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare, inherited heart condition.
This designation provides the company with more frequent interactions with the FDA along with the eligibility for priority review.
The company plans to initiate a Phase 1b study of SGT-501 in the fourth quarter of this year.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Solid Biosciences Inc Registered Shsmehr Nachrichten
| Keine Nachrichten verfügbar. |